CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17

Wilfrido D. Mojica, Romil Saxena, P. Starostik, R. T. Cheney

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aims: To determine the frequency of point mutation in c-kit in CD117+ small cell lung cancer (SCLC). A significant proportion of SCLCs have been documented to be CD117+, thereby signifying they express the c-kit gene product. This finding suggests this tumour may be a potential target for tyrosine kinase inhibitor (TKI) agents directed at c-kit. A point mutation in exon 17 of the c-kit gene, however, can abrogate the binding of TKIs. This being the case, immunohistochemistry is necessary to identify potential candidates for treatment with TKIs, but DNA sequence analysis may need to be performed to determine if these tumours will respond. Methods and results: Tumour cells of 23 cases of SCLC showing immunoreactivity for CD117 were laser capture microdissected from archived formalin-fixed paraffin-embedded tissue and the DNA isolated. PCR on exon 17 of the c-kit gene was performed and the amplified product sequenced. No point mutations were detected. Conclusions: The absence of mutations in exon 17 of CD117+ SCLC suggests this tumour may respond to therapy with TKI.

Original languageEnglish (US)
Pages (from-to)517-522
Number of pages6
JournalHistopathology
Volume47
Issue number5
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Viperidae
Point Mutation
Exons
Protein-Tyrosine Kinases
Neoplasms
Genes
DNA Sequence Analysis
Paraffin
Formaldehyde
Lasers
Immunohistochemistry
Polymerase Chain Reaction
Mutation
DNA
Therapeutics

Keywords

  • C-kit
  • CD117
  • PCR
  • Small cell lung cancer

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17. / Mojica, Wilfrido D.; Saxena, Romil; Starostik, P.; Cheney, R. T.

In: Histopathology, Vol. 47, No. 5, 11.2005, p. 517-522.

Research output: Contribution to journalArticle

Mojica, Wilfrido D. ; Saxena, Romil ; Starostik, P. ; Cheney, R. T. / CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17. In: Histopathology. 2005 ; Vol. 47, No. 5. pp. 517-522.
@article{ffa1a886a59a440d8ab77dca0da6e6eb,
title = "CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17",
abstract = "Aims: To determine the frequency of point mutation in c-kit in CD117+ small cell lung cancer (SCLC). A significant proportion of SCLCs have been documented to be CD117+, thereby signifying they express the c-kit gene product. This finding suggests this tumour may be a potential target for tyrosine kinase inhibitor (TKI) agents directed at c-kit. A point mutation in exon 17 of the c-kit gene, however, can abrogate the binding of TKIs. This being the case, immunohistochemistry is necessary to identify potential candidates for treatment with TKIs, but DNA sequence analysis may need to be performed to determine if these tumours will respond. Methods and results: Tumour cells of 23 cases of SCLC showing immunoreactivity for CD117 were laser capture microdissected from archived formalin-fixed paraffin-embedded tissue and the DNA isolated. PCR on exon 17 of the c-kit gene was performed and the amplified product sequenced. No point mutations were detected. Conclusions: The absence of mutations in exon 17 of CD117+ SCLC suggests this tumour may respond to therapy with TKI.",
keywords = "C-kit, CD117, PCR, Small cell lung cancer",
author = "Mojica, {Wilfrido D.} and Romil Saxena and P. Starostik and Cheney, {R. T.}",
year = "2005",
month = "11",
doi = "10.1111/j.1365-2559.2005.02259.x",
language = "English (US)",
volume = "47",
pages = "517--522",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17

AU - Mojica, Wilfrido D.

AU - Saxena, Romil

AU - Starostik, P.

AU - Cheney, R. T.

PY - 2005/11

Y1 - 2005/11

N2 - Aims: To determine the frequency of point mutation in c-kit in CD117+ small cell lung cancer (SCLC). A significant proportion of SCLCs have been documented to be CD117+, thereby signifying they express the c-kit gene product. This finding suggests this tumour may be a potential target for tyrosine kinase inhibitor (TKI) agents directed at c-kit. A point mutation in exon 17 of the c-kit gene, however, can abrogate the binding of TKIs. This being the case, immunohistochemistry is necessary to identify potential candidates for treatment with TKIs, but DNA sequence analysis may need to be performed to determine if these tumours will respond. Methods and results: Tumour cells of 23 cases of SCLC showing immunoreactivity for CD117 were laser capture microdissected from archived formalin-fixed paraffin-embedded tissue and the DNA isolated. PCR on exon 17 of the c-kit gene was performed and the amplified product sequenced. No point mutations were detected. Conclusions: The absence of mutations in exon 17 of CD117+ SCLC suggests this tumour may respond to therapy with TKI.

AB - Aims: To determine the frequency of point mutation in c-kit in CD117+ small cell lung cancer (SCLC). A significant proportion of SCLCs have been documented to be CD117+, thereby signifying they express the c-kit gene product. This finding suggests this tumour may be a potential target for tyrosine kinase inhibitor (TKI) agents directed at c-kit. A point mutation in exon 17 of the c-kit gene, however, can abrogate the binding of TKIs. This being the case, immunohistochemistry is necessary to identify potential candidates for treatment with TKIs, but DNA sequence analysis may need to be performed to determine if these tumours will respond. Methods and results: Tumour cells of 23 cases of SCLC showing immunoreactivity for CD117 were laser capture microdissected from archived formalin-fixed paraffin-embedded tissue and the DNA isolated. PCR on exon 17 of the c-kit gene was performed and the amplified product sequenced. No point mutations were detected. Conclusions: The absence of mutations in exon 17 of CD117+ SCLC suggests this tumour may respond to therapy with TKI.

KW - C-kit

KW - CD117

KW - PCR

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=27744596973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744596973&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2005.02259.x

DO - 10.1111/j.1365-2559.2005.02259.x

M3 - Article

C2 - 16242000

AN - SCOPUS:27744596973

VL - 47

SP - 517

EP - 522

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 5

ER -